Navigation Links
Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Oral Picoplatin Demonstrating Bioavailability
Date:4/21/2009

- Pharmacologic Data Presented at American Association for Cancer Research's 100th Annual Meeting 2009 -

SOUTH SAN FRANCISCO, Calif. and DENVER, April 21 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced the presentation of final data from a Phase 1 clinical study of an oral formulation of picoplatin in patients with solid tumors. Results showed that the bioavailability of oral picoplatin is nearly 100 percent at doses of 50 mg and 100 mg, indicating sufficient bioavailability to support further clinical development.

Picoplatin, the Company's lead product candidate, is a new generation platinum chemotherapy agent in clinical development to treat a variety of solid tumors. It was designed to overcome platinum resistance of the tumor, which remains a medical challenge for oncologists and patients, whose therapeutic options become limited. Poniard is currently evaluating an intravenous formulation of picoplatin in a pivotal Phase 3 trial in patients with small cell lung cancer (SCLC) and in Phase 2 trials in metastatic colorectal cancer (CRC) and metastatic castration-resistant prostate cancer (CRPC).

"The results of the Phase 1 trial demonstrating the oral bioavailability of picoplatin support the continued development of an oral formulation for multiple tumor indications," said Robert De Jager, M.D., chief medical officer of Poniard. "We believe that oral picoplatin may offer opportunities for studies in new indications and in combinations with other chemotherapeutics or with radiation therapy. The administration options for oral picoplatin may provide more convenience to cancer patients and could enable the potential of multiple combination therapies."

The picoplatin data were presented today in a poster ses
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Poniard Pharmaceuticals Announces Upcoming Conference Participation
2. Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update
3. Poniard Pharmaceuticals Reports Third Quarter 2008 Financial Results and Corporate Update
4. Poniard Pharmaceuticals Provides 2009 Clinical Data Goals for Picoplatin
5. Poniard Pharmaceuticals Announces Appointment of Greg Weaver as Chief Financial Officer
6. Poniard Pharmaceuticals Receives Going Concern Qualification
7. Poniard Pharmaceuticals to Present at Needham & Companys Cancer Therapeutics: Today & Tomorrow Conference
8. Poniard Pharmaceuticals to Focus Company Resources on Late-Stage Oncology Candidate Picoplatin Through Realignment of Research Organization
9. Poniard Announces Publication of Results of Picoplatin Phase 2 Study in Journal of Clinical Oncology
10. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
11. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... (PRWEB) March 06, 2015 Truly Nolen, ... pleased to announce the grand opening of their first ... Charlotte area down to the Fort Mill – Rock ... on February 27th, 2015 at their new location. ... 35 years of collective experience in the pest control ...
(Date:3/6/2015)... Austin, TX (PRWEB) March 06, 2015 ... transformational publishing company, created a unique ‘energy’ experiment ... people’s lives. , After quick ‘5 ... in more than 150+ countries reported their life ... of respondents reported positive results. , According to ...
(Date:3/6/2015)... (PRWEB) March 06, 2015 Fluid Running® ... Marathon qualifier, developed the Fluid Running® method ... before the Chicago marathon. She hit upon the trifecta ... group run, and a maximum-resistance, deep water running technique. ... unique no-impact, deep water running workout that made the ...
(Date:3/5/2015)... In 2014, the FDA approved 44 drugs, with ... scoring 4 drug approvals in the USA. The infectious ... drug products, followed by oncology therapy with 18% of ... CDK inhibitors keep on attracting large-cap pharmacos. Nivolumab and ... metastatic melanoma, and at present, they are being investigated ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 AxoGen, ... focused on the peripheral nerve repair market, reported record ... December 31, 2014 compared to $2.98 million in the ... its growth strategies. , “Our strong fourth quarter ... peripheral nerve repair products which is driving increased surgeon ...
Breaking Medicine News(10 mins):Health News:First Truly Nolen Franchise Opening in North Carolina 2Health News:250,000+ Person ‘Remote Energy’ Event has 94.2% of Respondents saying “Life Got Better” 2Health News:Fluid Running®, the Revolutionary, No-Impact Running Workout, Expands Nationally with New Training Workshop 2Health News:Fluid Running®, the Revolutionary, No-Impact Running Workout, Expands Nationally with New Training Workshop 3Health News:World Pharma Business and Large-Cap Companies Discussed by MP Advisors in In-demand Study Available at MarketPublishers.com 2Health News:World Pharma Business and Large-Cap Companies Discussed by MP Advisors in In-demand Study Available at MarketPublishers.com 3Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 2Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 3Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 4
... 27 An effective,cross-functional team lays the groundwork ... both initially and long-term. Leading,pharma companies calculate that ... for half of a drug,s success with the,other ... compound, according,to a study by Best Practices, LLC. ...
... The Clinical Trials Directive, which came into force ... harmonised framework for clinical drug research across Europe, ... findings presented at the European Cancer Conference (ECCO ... Hartmann, from European Consulting and Contracting in Oncology, ...
... 27 - Call for international Berthold ... Submissions Applications and proposals are now being ... developers and,researchers who do innovative work in the ... foundation Berthold Leibinger Stiftung is granted for,innovations pertaining ...
... Rendell,recently appointed Richard Snyder, M.D., senior vice president ... the state,s Chronic Care,Commission. Snyder took his oath ... other commission appointees during its first meeting. ... for Pennsylvanians,living with chronic health conditions such as ...
... Spain: In the largest and most rigorous study to ... found that marriages are no more likely than normal ... testicular cancer. , In fact, the study, presented today ... 14) in Barcelona, found most types of cancer resulted ...
... Has Gone Pink To Promote Breast Cancer Awareness, ... entered into,a partnership with Susan G. Komen for the ... with a spreader that features the pink breast,cancer awareness ... of National Breast Cancer Awareness Month and the program ...
Cached Medicine News:Health News:Creating Effective Cross-Functional Teams for Pharmaceutical Commercialization Success 2Health News:Clinical Trials Directive still hampering academic medical research 2Health News:Clinical Trials Directive still hampering academic medical research 3Health News:Prize for Cutting-Edge Laser Innovations 2Health News:Governor Rendell Appoints Dr. Richard Snyder of Independence Blue Cross to Chronic Care Commission 2Health News:Governor Rendell Appoints Dr. Richard Snyder of Independence Blue Cross to Chronic Care Commission 3Health News:Couples more likely to divorce if spouse develops cervical or testicular cancer 2Health News:Susan G. Komen for the Cure Partners With the Original Butter Bell(R) Crock Developer 2
(Date:3/5/2015)...  ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ... the approved abbreviated new drug application ("ANDA") for ... previously marketed by Teva Pharmaceuticals.  According to IMS ... approximately $39 million in 2014.   ... of ANI Pharmaceuticals, stated, "This acquisition further expands ...
(Date:3/5/2015)... Research and Markets ( http://www.researchandmarkets.com/research/4q7gwz/india_pharma ) ... Outlook 2015: Accelerating growth to the next level - ... to their offering. Domestic sales improved ... caused by the market,s reaction to the new drug ... to be healthy, as the momentum continues and improving ...
(Date:3/5/2015)... N.J. , March 5, 2015 Soligenix, ... stage biopharmaceutical company committed to developing products that address ... and biodefense, announced today that its President and Chief ... give a corporate presentation at the 27 th ... , on Tuesday, March 10, 2015 at 1:00 ...
Breaking Medicine Technology:ANI Pharmaceuticals Acquires Generic Drug Product from Teva Pharmaceuticals 2ANI Pharmaceuticals Acquires Generic Drug Product from Teva Pharmaceuticals 3India Pharma Outlook 2015: Accelerating growth to the next level - Moving up the value chain beyond Generics 2India Pharma Outlook 2015: Accelerating growth to the next level - Moving up the value chain beyond Generics 3Soligenix to Present at the 27th Annual ROTH Conference 2Soligenix to Present at the 27th Annual ROTH Conference 3
... Md., Nov. 15, 2011 Since its inception ... with a Maryland Clinical Laboratory license, has focused ... for infectious diseases and providing contract research services ... The advanced molecular diagnostics technology Clongen Laboratories ...
... Nov. 15, 2011 Reportlinker.com announces that ... in its catalogue: The ... http://www.reportlinker.com/p0203104/The-Outlook-for-Pharmaceuticals-in-Latin-America.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmacies_and_Drug_Stores ... developments are making Latin America more attractive ...
Cached Medicine Technology:Clongen Laboratories Announces Formation of Separate Clinical Diagnostics and Contract Research Divisions 2The Outlook for Pharmaceuticals in Latin America 2The Outlook for Pharmaceuticals in Latin America 3The Outlook for Pharmaceuticals in Latin America 4The Outlook for Pharmaceuticals in Latin America 5The Outlook for Pharmaceuticals in Latin America 6The Outlook for Pharmaceuticals in Latin America 7
Provides 30% more illumination, high light output for true tissue. Wide-angle viewing lens, sealed system for pneumatic otoscopy....
... FE and FSE are a new series ... microtome is outside of the cryochamber, which ... as faster temperature adjustment. Simple, multi-lingual touch-screen ... controls on the main touch-screen display. Angle ...
A standard, durable and reliable indirect....
Designed to retain the desired curve during oral intubation....
Medicine Products: